Merck announces phase 3 keynote-b96 trial met secondary endpoint of overall survival (os) in all comers population of patients with platinum-resistant recurrent ovarian cancer

Rahway, n.j.--(business wire)---- $mrk #mrk--merck (nyse: mrk), known as msd outside of the united states and canada, today announced that the phase 3 keynote-b96 trial, also known as engot-ov65, met its secondary endpoint of overall survival (os) for the treatment of patients with platinum-resistant recurrent ovarian cancer in all comers. the trial studied keytruda® (pembrolizumab), merck's anti-pd-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for these patients. as pr.
OS Ratings Summary
OS Quant Ranking